Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company Deals

Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors

Fineline Cube Sep 20, 2023

Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...

Policy / Regulatory

NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion

Fineline Cube Sep 20, 2023

The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug...

Company Drug

FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted priority review status to an indication...

Company Deals

Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals

Fineline Cube Sep 20, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into...

Company Drug

Astellas Pharma’s Xtandi NDA for mHSPC Treatment Accepted by China’s CDE

Fineline Cube Sep 20, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Drug

Pfizer’s Litfulo Earns EU Approval as First Treatment for Severe Alopecia Areata in Teens

Fineline Cube Sep 20, 2023

Pfizer (NYSE: PFE) has been granted registration authorization by the European Commission (EC) for Litfulo...

Company Deals

Tianjin Century Kangtai Biomedical Raises Hundreds of Millions in Series A+ and B Financings

Fineline Cube Sep 20, 2023

Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of...

Company Drug

Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial

Fineline Cube Sep 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from...

Company Drug

Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study

Fineline Cube Sep 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine

Fineline Cube Sep 20, 2023

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing...

Company Deals

Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion

Fineline Cube Sep 20, 2023

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with...

Company Deals

Cure Genetics and Frametact Ltd Partner on AAV Vectors for Neurological Diseases

Fineline Cube Sep 19, 2023

Suzhou-based Cure Genetics has entered into a collaboration and licensing agreement with Hong Kong’s Frametact...

Company Drug

Caliway Biopharmaceuticals’ CBL-514 Achieves Milestones in Dercum’s Disease Trial

Fineline Cube Sep 19, 2023

Taiwan-based Caliway Biopharmaceuticals, a specialist in medical aesthetics and inflammatory medicine, has announced that its...

Company Deals

BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion

Fineline Cube Sep 19, 2023

Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative...

Company Deals

Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round

Fineline Cube Sep 19, 2023

China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million...

Company Medical Device

MicroPort MedBot’s SkyWalker Robot Approved for Orthopedic Surgery by NMPA

Fineline Cube Sep 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Company Drug

Zhejiang Medicine Gets NMPA Approval for NCB003 Clinical Study for Advanced Solid Tumors

Fineline Cube Sep 19, 2023

Zhejiang Medicine Co., Ltd (SHA: 600216), a China-based pharmaceutical company, has announced that it has...

Company Drug

Zelgen Biopharmaceuticals’ rhTSH Achieves Primary Endpoint in Phase III Study

Fineline Cube Sep 19, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that its...

Policy / Regulatory

China’s CDE Proposes Removal of Ambroxol Inhalation Solution and Four Other Drugs

Fineline Cube Sep 19, 2023

The Center for Drug Evaluation has issued a notification concerning the Chemical Generic Drug Reference...

Company Drug

CSBIO’s Albenatide Shows Positive Results in Two Phase III Diabetes Trials

Fineline Cube Sep 19, 2023

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced encouraging results from two...

Posts pagination

1 … 426 427 428 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.